Celebrity Users and Public Endorsements
Ozempic, the brand name for semaglutide made by Novo Nordisk, has attracted a long list of Ozempic famosos who have publicly acknowledged weight-loss use or prescribed off-label use. Elon Musk stated in 2023 that he used Wegovy, a higher-dose sibling drug from Novo Nordisk, and has since referenced GLP-1 therapies in interviews and posts. Tesla and SpaceX CEO Musk's public comments contributed to a wave of media coverage linking tech billionaires and Hollywood figures to the drug Forbes. Other reported users include actors, musicians, and social-media influencers, though Novo Nordisk has not released an official celebrity endorsement list.
Public discussion of Ozempic famosos has pushed semaglutide into mainstream culture, with U.S. prescriptions surging in 2024 and early 2025. The U.S. Food and Drug Administration approved Wegovy for chronic weight management in 2021, and expanded indications for cardiovascular risk reduction, which reinforced interest among high-profile figures focused on longevity and performance. Celebrity usage is often cited in earnings calls as evidence of strong demand, even when companies do not name individuals directly SEC Filing.
Market Impact and Company Valuations
Novo Nordisk Valuation and Revenue
Novo Nordisk became one of Europe's most valuable companies as Ozempic and Wegovy drove record revenue growth. In 2024, the company raised full-year sales guidance multiple times, citing strong demand in the United States and expanding uptake in other markets. Market capitalization surged to levels placing Novo Nordisk among the top global healthcare firms, with shares reacting sharply to quarterly sales updates and supply announcements Forbes.
Analysts track Ozempic famosos as a qualitative signal of brand prestige and demand, even though Novo Nordisk does not disclose individual patient identities. The company's focus on manufacturing capacity, cold-chain logistics, and payer negotiations shapes how quickly prescriptions can be filled for both celebrity and general patients. Investor presentations highlight that GLP-1 receptor agonists represent a multi-billion-dollar growth segment, with Ozempic and Wegovy as the primary revenue drivers through 2025 and beyond.
Regulatory and Competitive Landscape
FDA Approvals and Off-Label Use
The FDA approved semaglutide under the Ozempic name for type 2 diabetes in 2017 and later approved Wegovy for weight management. Off-label prescribing for weight loss remains common, and many Ozempic famosos have acknowledged using the drug for this purpose while noting the importance of medical supervision. The FDA continues to monitor compounded versions of semaglutide, which have faced shortages and safety concerns, and has taken enforcement actions against some pharmacies FDA.
Competitors and Pipeline Therapies
Competitors including Eli Lilly with tirzep